Histone H2A.Z (H2A.Z) (H2A.Z)

Histone H2A.Z is a highly conserved H2A histone variant that plays a critical role in regulating chromatin structure and gene expression. Unlike canonical histones, H2A.Z is deposited into specific genomic regions, such as promoters and enhancers, by specialized remodeling complexes like SRCAP and p400/TIP60 (UniProt P0C0S8). Its presence can either facilitate or repress transcription depending on the cellular context and its post-translational modifications, such as acetylation or ubiquitination (PubMed: 28611434). In many cancers, H2A.Z is significantly overexpressed and is associated with increased cell proliferation, epithelial-mesenchymal transition, and poor clinical outcomes (PubMed: 31515460). Consequently, it has emerged as a potential therapeutic target and diagnostic biomarker in oncology. Current pharmacological strategies often focus on inhibiting the enzymes responsible for its deposition or modification, as well as using nucleic acid-based therapies to reduce its expression (PubMed: 33806134). Because H2A.Z is essential for normal development, therapeutic interventions must carefully balance efficacy against potential systemic toxicity.

Other names

H2AFZH2AZH2A.Z-1H2A/zH2A histone family member Z

Modulation of chromatin accessibility through the inhibition of H2A.Z deposition by the SRCAP complex or the reduction of H2A.Z protein levels via nucleic acid-based therapies.